PT
PTIX.US Protagenic Therapeutics
- Market cap
- USD 815K
- P/E
- 0.2x
- P/B
- 3.35x
- ROE
- -291.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is PTIX.US undervalued?
Graham numberThe Graham number of Protagenic Therapeutics cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Protagenic Therapeutics fundamental analysis
No fundamental analysis for Protagenic Therapeutics yet.
Protagenic Therapeutics stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. The company was founded in 2004 and is based in New York, New York.
Full company profileProtagenic Therapeutics financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Protagenic Therapeutics annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Gross Profit | -534.00 | -148.00 | -347.00 | -339.00 | -286.00 | - | -30.00 | -28.2K | -50.3K | -37.7K | -22.4K |
| Operating Income | -2.23M | -2.37M | -2.31M | -2.09M | -2.55M | -4.14M | -3.56M | -4.53M | -5.70M | -5.83M | -3.26M |
| EBITDA | -2.27M | -2.37M | -2.31M | -2.09M | -2.55M | -4.14M | -3.42M | -4.50M | -5.48M | -7.10M | -3.25M |
| Net Income | -2.28M | -2.26M | -2.56M | -1.75M | -2.55M | -4.52M | -3.56M | -5.00M | -5.53M | -5.16M | -3.26M |
| EPS | -1.72 | -0.88 | -1.00 | -0.68 | -0.99 | -1.23 | -0.82 | -1.15 | -1.13 | -2.66 | -1.80 |
| Balance Sheet | |||||||||||
| Total Assets | 3.16M | 1.78M | 697K | 842K | 879K | 11.1M | 8.04M | 4.32M | 1.96M | 2.13M | 2.08M |
| Total Liabilities | 685K | 562K | 908K | 1.48M | 2.03M | 1.12M | 1.12M | 655K | 943K | 6.82M | 1.15M |
| Shareholders' Equity | 2.48M | 1.22M | -211K | -634K | -1.15M | 9.94M | 6.92M | 3.67M | 1.01M | -2.39M | 1.12M |
| Cash & Short-term Investments | 3.10M | 1.69M | 613K | 799K | 671K | 10.4M | 7.98M | 4.06M | 1.84M | 2.21M | 76.9K |
| Total Debt | - | - | - | 279K | 1.37M | 318K | 344K | - | - | 3.16M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.14M | -1.38M | -1.07M | -488K | -1.35M | -2.80M | -1.99M | -3.70M | -4.22M | -4.14M | -2.87M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 | 1.81K | 150K | 0.00 | 3.00 | 6.59K |
| Free Cash Flow | -1.14M | -1.38M | -1.07M | -488K | -1.35M | -2.80M | -2.00M | -3.85M | -4.22M | -4.14M | -2.87M |
| Ratios | |||||||||||
| ROE | -91.9% | -185.4% | - | - | - | -45.5% | -51.4% | -136.3% | -545.3% | - | -291.6% |
| ROA | -72.0% | -126.9% | -367.1% | -207.9% | -289.9% | -40.9% | -44.2% | -115.7% | -282.5% | -241.8% | -156.6% |
| Debt to Equity | - | - | - | - | - | 0.03x | 0.05x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Protagenic Therapeutics dividends
Protagenic Therapeutics has not paid dividends in the last 9 fiscal years.
Last stock split: 1:14 on May 5, 2025.
Who owns Protagenic Therapeutics
- Insiders 6.20%
- Institutions 3.69%
- Public & others 90.11%
- Shares outstanding 1.81M
- Free float 1.72M
Top funds holding PTIX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SSgA U.S. Total Market Index Strategy | 36.00 | 0.00% | 0.00% | Sep 2025 |
Top institutions holding PTIX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| DRW Securities, LLC | 41.8K | 2.31% | -2.50% | Mar 2026 |
| United Financial Planning Group LLC | 17.00 | 0.00% | 0.00% | Mar 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| HARBOR INVESTMENT ADVISORY, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Advisor Group Holdings, Inc. | 0.00 | 0.00% | -100.00% | Mar 2026 |
| CoreCap Advisors, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Bank of America Corp | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Mar 2026 |
Protagenic Therapeutics company profile
- Company name
- Protagenic Therapeutics
- Ticker
- PTIX.US
- Exchange
- USA Stocks
- Listed since
- Jan 5, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 149 Fifth Avenue, New York, NY, United States, 10010
- Phone
- 212 994 8200
- Website
- protagenic.com
About Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. The company was founded in 2004 and is based in New York, New York.
Protagenic Therapeutics management
4- Dr. Garo H. Armen Ph.D.Executive Chairman · born 1953
- Mr. William Nichols Jr.President · born 1975
- Dr. Robert Benjamin Stein M.D., Ph.D.Chief Medical Officer · born 1951
- Dr. Andrew Slee Ph.D.Chief Development Officer · born 1950